Conference Call with Caplin Point Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Caplin Point Laboratories announced Q3FY25 results Revenue: Rs 493.0 crore compared to Rs 435.5 crore during Q3FY24, change 13.2%. EBITDA: Rs 193.7 crore compared to Rs 159.5 crore during Q3FY24, change 21.4%. PBT: Rs 177.3 crore compared to Rs 145.4 crore during Q3FY24, change 21.9%. PAT: Rs 140.1 crore compared to Rs 119.8 crore during Q3FY24, change 16.9%. Gross Margin for Q3FY25 is 60.4% vs 56.3% in Q3 FY24. EBITDA Margin for Q3FY25 is at 36.9% vs 35.2% in Q3 FY24. As of 31st December 2024, Inventories are at Rs 333 crore - 52% Stock at the warehouses, close to the customer; In Transit 18%; 30% in India. Receivables is at 118 days. As of 31st December, 2024 Free Cash reserves are at Rs 1,081 crore and Total Liquid Assets at Rs 2,042 crore. C.C. Paarthipan, Chairman, said: We’re happy to report another strong set of numbers for this quarter, underlining our sharp focus on consistency in all areas. The company has shown encouraging progress within a very short period when it comes to the launch of our own label in the US, and with consistent on-time approvals, we’re confident that this entity will deliver robust growth to the organization. We’re making good progress in our key emerging markets of Mexico and Chile, and we can start to see tangible growth from these areas in the next couple of years. The company is well positioned for continued growth in all parameters, with benchmark cashflows for multiple years to come. Result PDF